Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial
Journal of the American Academy of Dermatology Oct 04, 2017
William WN, et al. - The response rate to gefitinib in patients with cutaneous squamous cell carcinoma (CSCC) not amenable to curative therapy with the inclusion of surgery or radiation was determined. A modest activity was substantiated by gefitinib in the case of incurable CSCC, with a favorable adverse event profile.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
